Obesity News and Research

Latest Obesity News and Research

Youngsters create short films to address obesity and eating disorders

Youth homelessness and eating disorders are two areas of health highlighted by young people in Cardiff in a project that uses digital technology to create short films which detail public health issues.

16 Mar 2010

High ABI may indicate risk for future heart attacks

The prevalence of abnormal ankle-brachial index (ABI) test results among individuals tested for peripheral arterial disease (PAD)—and who are not considered at high risk of a coronary heart event by Framingham-based risk factors—is high and provides another way to identify those who may be at risk for future heart attacks, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

15 Mar 2010

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

15 Mar 2010

Rhythm Pharmaceuticals completes $21M Series A equity financing

Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that it has completed the first close on its Series A equity financing of $21 million. The financing was led by MPM Capital and New Enterprise Associates. The funds will be used to develop products licensed from Ipsen.

15 Mar 2010

NDA for BYDUREON: FDA issues complete response letter

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ (exenatide for extended-release injectable suspension).

15 Mar 2010

Orexigen Therapeutics, Patheon sign long-term agreement for commercial manufacturing of Contrave

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.

15 Mar 2010

Painful periods at early age doubles risk of endometriosis

Queensland Institute of Medical Research scientists have identified a new link between strong period pain experienced in adolescence and early adulthood and the risk of endometriosis.

15 Mar 2010

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.

15 Mar 2010

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower).

15 Mar 2010

Childhood obesity: Genetic variation could be a factor

Increasing childhood obesity has worried governments and public health advisers in many countries. But a study of 300 children with severe obesity by the University of Cambridge and the Wellcome Trust Sanger Institute, suggest the problem may be more complicated than simply bad diet, overeating, or lack of exercise.

12 Mar 2010

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

12 Mar 2010

Tackling childhood obesity: Chidren need to be involved in physical activity program planning process

Getting children involved in finding ways to become more physically active can not only make them more aware of local recreational opportunities, but can even help increase their own physical activity.

12 Mar 2010

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.

12 Mar 2010

Hamilton Health Sciences establishes new research facility

Hamilton's role as one of the world's leading centres in cardiac, vascular and stroke research was amplified today with the grand opening of the David Braley Cardiac, Vascular and Stroke Research Institute at the Hamilton General Hospital site of Hamilton Health Sciences.

12 Mar 2010

Collaborative center established to reduce obesity-related deaths in African-American and Latino communities

A $6 million grant from the National Heart, Lung and Blood Institute (NHLBI) has funded the creation of ORBIT: Obesity Related Behavioral Intervention Trials to focus on reducing obesity and obesity-related deaths in New York City's African-American and Latino communities.

11 Mar 2010

Age-related macular degeneration affects central vision in older Americans

Indianapolis resident Harry Traugott was an active retiree, participating in community events, driving and even teaching English as a second language at two community centers. He’d been diagnosed with age-related macular degeneration (AMD), but the disease had not caused significant vision loss. It wasn’t until he had trouble seeing while driving, watching television

11 Mar 2010

Regence acquires assets of Kinetix Living

As part of its continued focus on developing programs designed to meet employers' needs, Regence has acquired the assets of Kinetix Living Corp., a Seattle-based company that provides customized health and nutrition programs to corporate clients and individuals throughout the country.

11 Mar 2010

Sleep disorders may increase risk of cardiovascular and metabolic diseases

Many Americans will lose an hour of sleep on March 14, the first day of daylight-saving time, when clocks are set ahead one hour at 2 a.m. local standard time—making it harder to wake up, causing difficulty in staying alert and increasing the chance of sleepy-driving car crashes.

11 Mar 2010

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

NeuroSearch today announced that further analysis of the data from the MermaiHD study with Huntexil(R) (pridopidine) for the treatment of Huntington's disease supports potential disease modifying properties of the drug.

11 Mar 2010

USA/Ireland Functional Foods conference to focus on science of gut function and response to diet

Understanding the science of how the human gut functions and the role that diet plays in human health will be explored at a major International Functional Foods conference in Cork, this week. Foods have an enormous role to play in keeping people healthy and many foods have properties that can enhance the health of those that consume them.

10 Mar 2010

Obesity News and Research

Latest Obesity News and Research

Youngsters create short films to address obesity and eating disorders

High ABI may indicate risk for future heart attacks

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Rhythm Pharmaceuticals completes $21M Series A equity financing

NDA for BYDUREON: FDA issues complete response letter

Orexigen Therapeutics, Patheon sign long-term agreement for commercial manufacturing of Contrave

Painful periods at early age doubles risk of endometriosis

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Childhood obesity: Genetic variation could be a factor

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Tackling childhood obesity: Chidren need to be involved in physical activity program planning process

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Hamilton Health Sciences establishes new research facility

Collaborative center established to reduce obesity-related deaths in African-American and Latino communities

Age-related macular degeneration affects central vision in older Americans

Regence acquires assets of Kinetix Living

Sleep disorders may increase risk of cardiovascular and metabolic diseases

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

USA/Ireland Functional Foods conference to focus on science of gut function and response to diet

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Obesity News and Research

Latest Obesity News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in